-
Mashup Score: 57
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The value of anti-CD30 CAR T cells in Hodgkin lymphoma - 23 day(s) ago
The use of chimeric antigen receptor (CAR) T cells in haematological malignancies is becoming increasingly widespread, with several authorised drugs and many patients benefiting from their efficacy and manageable tolerance in the short and medium term.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52
Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52
Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6FDA Accepts Resubmitted BLA for Denileukin Diftitox in R/R CTCL - 1 month(s) ago
The regulatory agency sets a Prescription Drug User Fee Act date of August 13, 2024, for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Iopofosine I 131 monotherapy elicited durable responses and was associated with a tolerable safety profile in patients with heavily pretreated, multi-class refractory Waldenström macroglobulinemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 50
Leukemia – Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
NEW: first-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin achieves a complete response of 85% (29 of 34) in patients w/ advanced extranodal natural killer/T cell lymphoma. Results of the ph2 SPIRIT trial #lymsm https://t.co/cxHjB4ppSo https://t.co/3ZY7jXIWWV